Actuate Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Actuate Therapeutics, Inc. (ACTU) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 1.98% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-26
- Actuate Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2025 was 1.98%, a 68.22% decline from fiscal 2024.
- Actuate Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 6.23%, a 34.07% decline from fiscal 2023.
- Actuate Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 9.45%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2025-12-31 | 1.98% 10-K · filed 2026-03-26 |
| 2024-12-31 | 6.23% 10-K · filed 2026-03-26 |
| 2023-12-31 | 9.45% 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |